Assessment
Compulsory Licensing is likely to be of value ONLY to large countries with substantial pharmaceutical industries such as India, China and Brazil
Drugs that can be used with minimal monitoring should be the first candidates
HIV AIDS drugs may not be good candidates because of monitoring costs and prolonged duration of use
Many factors other than manufacturing cost affect access and correct use